Clinical trial
Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis…
NCT00157690 · McMaster University, Other · Completed
Key facts
| NCT number | NCT00157690 |
|---|---|
| Title | Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients |
| Official title | A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients |
| Lead sponsor | McMaster University, Other |
| Collaborators | Centre hospitalier de l'Université de Montréal (CHUM) London Health Sciences Centre University of Calgary McGill University Laval University Merck Frosst Canada Ltd. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis, Osteoporosis, Bone Diseases, Metabolic |
| Intervention type | Drug |
| Interventions | Alendronate, Placebo |
| Enrollment | 56 |
| Start date | Dec 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 12, 2005 |
| Last update posted | Oct 23, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: